Long-acting bronchodilators improve health related quality of life in patients with COPD.

[1]  C. Cates,et al.  Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. , 2015, The Cochrane database of systematic reviews.

[2]  J. Lammers,et al.  Evaluation of Quality of Life instruments for use in COPD care and research: a systematic review. , 2013, International journal of nursing studies.

[3]  E. Bateman,et al.  Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. , 2013, The Lancet. Respiratory medicine.

[4]  P. Poole,et al.  Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. , 2012, The Cochrane database of systematic reviews.

[5]  T. Perez,et al.  Patient-centred assessment of COPD in primary care: experience from a cross-sectional study of health-related quality of life in Europe. , 2012, Primary care respiratory journal : journal of the General Practice Airways Group.

[6]  E. Kerwin,et al.  Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study , 2012, European Respiratory Journal.

[7]  E. Bateman,et al.  Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study , 2012, European Respiratory Journal.

[8]  L. Hang,et al.  Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: A 12‐week, placebo‐controlled study , 2012, Respirology.

[9]  M. Cazzola,et al.  Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. , 2012, Primary care respiratory journal : journal of the General Practice Airways Group.

[10]  K. Hirata,et al.  Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial , 2011, Respiratory research.

[11]  E. Kerwin,et al.  Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies. , 2011, Clinical therapeutics.

[12]  S. Sugiyama,et al.  Effects of inhaled tiotropium plus transdermal tulobuterol versus tiotropium alone on impulse oscillation system (IOS)-assessed measures of peripheral airway resistance and reactance, lung function and quality of life in patients with COPD: a randomized crossover study. , 2011, Pulmonary pharmacology & therapeutics.

[13]  Dave Singh,et al.  Safety of indacaterol in the treatment of patients with COPD , 2011, International journal of chronic obstructive pulmonary disease.

[14]  C. Vogelmeier,et al.  Efficacy of indacaterol in the treatment of patients with COPD. , 2011, Primary care respiratory journal : journal of the General Practice Airways Group.

[15]  Roger Owen,et al.  Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled study. , 2011, Chest.

[16]  G. Canonica,et al.  Chronic Obstructive Pulmonary Disease Patient Well-Being and Its Relationship with Clinical and Patient-Reported Outcomes: A Real-Life Observational Study , 2011, Respiration.

[17]  H. Magnussen,et al.  Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease , 2011, Respiratory research.

[18]  G. Canonica,et al.  Disability in COPD and its relationship to clinical and patient-reported outcomes , 2011, Current medical research and opinion.

[19]  N. Hanania,et al.  The Safety and Efficacy of Arformoterol and Formoterol in COPD , 2011, COPD.

[20]  M. Hoshino,et al.  Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease , 2011, Respirology.

[21]  E. Bateman,et al.  A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. , 2010, Respiratory medicine.

[22]  M. Decramer,et al.  Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial. , 2010, Respiratory medicine.

[23]  R. Dahl,et al.  Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison , 2010, European Respiratory Journal.

[24]  J. Bousquet,et al.  Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GA2LEN taskforce position paper , 2010, Allergy.

[25]  J. Lötvall,et al.  Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. , 2010, American journal of respiratory and critical care medicine.

[26]  Michael Rudolf,et al.  Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance , 2010, BMJ : British Medical Journal.

[27]  H. Magnussen,et al.  Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD , 2010, Thorax.

[28]  M. Decramer,et al.  Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT® trial , 2010, European Respiratory Journal.

[29]  R. Dahl,et al.  Aclidinium bromide provides long-acting bronchodilation in patients with COPD. , 2010, Pulmonary pharmacology & therapeutics.

[30]  M. Decramer,et al.  Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. , 2009, American journal of respiratory and critical care medicine.

[31]  M. Decramer,et al.  Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial , 2009, The Lancet.

[32]  D. D. Briggs,et al.  Evaluation of withdrawal of maintenance tiotropium in COPD. , 2009, Respiratory medicine.

[33]  M. Decramer,et al.  Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial , 2009, European Respiratory Journal.

[34]  E. Kerwin,et al.  Efficacy and Safety of Nebulized Formoterol as Add-on Therapy in COPD Patients Receiving Maintenance Tiotropium Bromide , 2009, Drugs.

[35]  K. Kurashima,et al.  Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone , 2009, Respirology.

[36]  D. Tashkin,et al.  Formoterol and Tiotropium Compared With Tiotropium Alone for Treatment of COPD , 2009, COPD.

[37]  N. Ambrosino,et al.  Tiotropium and exercise training in COPD patients: Effects on dyspnea and exercise tolerance , 2008, International journal of chronic obstructive pulmonary disease.

[38]  C. Vogelmeier,et al.  Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. , 2008, Respiratory medicine.

[39]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[40]  M Cazzola,et al.  Outcomes for COPD pharmacological trials: From lung function to biomarkers. , 2008, Revista portuguesa de pneumologia.

[41]  A. Lindberg,et al.  Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. , 2008, Primary care respiratory journal : journal of the General Practice Airways Group.

[42]  T. Perez,et al.  Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD , 2008, International journal of chronic obstructive pulmonary disease.

[43]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[44]  M. Littner,et al.  Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. , 2008, Respiratory medicine.

[45]  T. Welte,et al.  Once versus twice daily formoterol via Novolizer for patients with moderate to severe COPD--a double-blind, randomised, controlled trial. , 2008, Pulmonary pharmacology & therapeutics.

[46]  N. Gross,et al.  Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients. , 2008, Respiratory medicine.

[47]  S. Han,et al.  The Combination of Tiotropium and Budesonide in the Treatment of Chronic Obstructive Pulmonary Disease , 2007, Journal of Korean medical science.

[48]  S. Sahn,et al.  Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. , 2007, Clinical therapeutics.

[49]  P. Jones.  Activity Limitation and Quality of life In COPD , 2007, COPD.

[50]  U. S. Department of Health and Human Services FDA Cen Research,et al.  Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance , 2006, Health and quality of life outcomes.

[51]  D. D. Briggs,et al.  Tiotropium in COPD patients not previously receiving maintenance respiratory medications. , 2006, Respiratory medicine.

[52]  F. Bart,et al.  The Effect of Tiotropium on Hyperinflation and Exercise Capacity in Chronic Obstructive Pulmonary Disease , 2006, Respiration.

[53]  R. Stockley,et al.  Addition of salmeterol to existing treatment in patients with COPD: a 12 month study , 2006, Thorax.

[54]  S. Kesten,et al.  Absence of Electrocardiographic Findings and Improved Function with Once‐Daily Tiotropium in Patients with Chronic Obstructive Pulmonary Disease , 2005, Pharmacotherapy.

[55]  K. Rabe,et al.  Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. , 2005, Respiratory medicine.

[56]  R. Casaburi,et al.  Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. , 2005, Chest.

[57]  G. Guyatt,et al.  Measurement Properties and Interpretability of the Chronic Respiratory Disease Questionnaire (CRQ) , 2005, COPD.

[58]  P. Bello,et al.  International Study Group , 2004 .

[59]  D. Patrick,et al.  The assessment of health status among patients with COPD , 2003, European Respiratory Journal.

[60]  C. Boshoff,et al.  Health outcomes following treatment for 6 months with once daily tiotropium compared with twice daily salmeterol in patients with COPD , 2003, Thorax.

[61]  T. Bengtsson,et al.  Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study , 2002, European Respiratory Journal.

[62]  E. Bateman,et al.  A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. , 2002, Chest.

[63]  S. K. Chhabra,et al.  An evaluation of salmeterol in the treatment of chronic obstructive pulmonary diseases. , 2002, The Indian journal of chest diseases & allied sciences.

[64]  R. Goldstein,et al.  The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease. , 2002, Canadian respiratory journal.

[65]  G. Della Cioppa,et al.  Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. , 2002, Chest.

[66]  J. Spertus,et al.  Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study). , 2002, American heart journal.

[67]  Gordon H Guyatt,et al.  Methods to explain the clinical significance of health status measures. , 2002, Mayo Clinic proceedings.

[68]  R. Zuwallack,et al.  A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease , 2002, European Respiratory Journal.

[69]  J. V. van Noord,et al.  Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium , 2002, European Respiratory Journal.

[70]  R. Dahl,et al.  Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[71]  R. Zuwallack,et al.  Use of a Long-acting Inhaled β2-Adrenergic Agonist, Salmeterol Xinafoate, in Patients with Chronic Obstructive Pulmonary Disease , 2001 .

[72]  P. Barnes,et al.  Chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[73]  P. Paggiaro,et al.  Salmeterol versus slow-release theophylline in patients with reversible obstructive pulmonary disease. , 1999, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[74]  L. Squassante,et al.  Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease , 1998 .

[75]  P. Jones,et al.  Quality of life changes in COPD patients treated with salmeterol. , 1997, American journal of respiratory and critical care medicine.

[76]  A. Morice,et al.  An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) , 1997, The European respiratory journal.

[77]  A J Morales,et al.  Quality of Life Assessment , 1996, Seminars in reproductive endocrinology.

[78]  I. Wilson,et al.  Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. , 1995, JAMA.

[79]  P. Jones,et al.  A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. , 1992, The American review of respiratory disease.

[80]  P. Jones,et al.  The St George's Respiratory Questionnaire. , 1991, Respiratory medicine.

[81]  P. Poole,et al.  Tiotropium versus placebo for chronic obstructive pulmonary disease. , 2012, The Cochrane database of systematic reviews.

[82]  C. Cates,et al.  Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease. , 2012, The Cochrane database of systematic reviews.

[83]  F. Maltais,et al.  A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. , 2007, Canadian respiratory journal.

[84]  T. Lasserson,et al.  Inhaled corticosteroids for stable chronic obstructive pulmonary disease. , 2007, The Cochrane database of systematic reviews.

[85]  F. Maltais,et al.  Tiotropium in Combination with Placebo, Salmeterol, or Fluticasone–Salmeterol for Treatment of Chronic Obstructive Pulmonary Disease A Randomized Trial , 2007 .

[86]  J. Ware.  SF-36 health survey: Manual and interpretation guide , 2003 .

[87]  P. Jones,et al.  Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluation. , 2003, Respiratory medicine.

[88]  V. Brusasco,et al.  CHRONIC OBSTRUCTIVE PULMONARY DISEASE Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD , 2003 .

[89]  Ad J. J. M. Vingerhoets,et al.  Quality of life assessment , 2001 .

[90]  A. Vingerhoets.  Assessment in behavioural medicine , 2001 .

[91]  R. Sanderman,et al.  Assessment in behavioural medicine , 2001 .

[92]  R. Zuwallack,et al.  Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[93]  B. Spilker,et al.  Quality of life and pharmacoeconomics in clinical trials , 1996 .

[94]  John E. Ware,et al.  SF-36 Health Survey. , 1990 .